A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Condition:   Atopic Dermatitis Interventions:   Drug: BxC-I17e;   Drug: Placebo Sponsor:   Brexogen Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials